Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Letter to the Editor

Page Path

HOME
ARTICLE CATEGORY
Letter to the Editor

Letter to the Editor

Current burden of MASLD, MetALD, and hepatic fibrosis among US adults with prediabetes and diabetes, 2017–2023

Donghee Kim, Rohit Loomba, Aijaz Ahmed

Clin Mol Hepatol. 2025;31(3):e235-e238. Published online December 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.1150

View: 1822 Download: 193 Crossref: 3

What is new in the 2024 Chinese guidelines for fatty liver disease?

Rui-Xu Yang, Vincent Wai-Sun Wong, Jian-Gao Fan

Clin Mol Hepatol. 2025;31(3):e239-e246. Published online January 21, 2025

DOI: https://doi.org/10.3350/cmh.2024.1165

View: 922 Download: 68

Letter to the editor on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”

Chi-Kuei Hsu, Po-Yu Huang, Chih-Cheng Lai

Clin Mol Hepatol. 2025;31(3):e247-e248. Published online February 6, 2025

DOI: https://doi.org/10.3350/cmh.2025.0073

View: 759 Download: 37

Classification of microvascular invasion of hepatocellular carcinoma: Different standards, common goals: Letter to the editor on “Classification of microvascular invasion of hepatocellular carcinoma: Correlation with prognosis and magnetic resonance imaging”

Wei Chen, Yihui Rong, Tianshi Ma, Weiwei Shi, Wei Chen, Hang Jiang

Clin Mol Hepatol. 2025;31(3):e249-e251. Published online February 18, 2025

DOI: https://doi.org/10.3350/cmh.2025.0167

View: 825 Download: 62

Letter to the editor on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”

Weixiong Zhu, Xuefan Zeng, Zengxi Yang, Yusheng Cheng, Wence Zhou

Clin Mol Hepatol. 2025;31(3):e252-e253. Published online February 26, 2025

DOI: https://doi.org/10.3350/cmh.2025.0189

View: 1112 Download: 62

Prevalence of steatotic liver disease and associated fibrosis in the general population: An epidemiological survey: Letter to the editor on “Epidemiology of metabolic dysfunction-associated steatotic liver disease”

Lin Guan, Xinhe Zhang, Shanghao Liu, Xiaolong Qi, Yiling Li

Clin Mol Hepatol. 2025;31(2):e145-e148. Published online October 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0921

View: 1510 Download: 81

Treatment response to nucleos(t)ide analogs in chronic hepatitis B with mildly elevated alanine aminotransferase: Letter to the editor on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial”

Jian Wang, Fei Cao, Chuanwu Zhu, Chao Wu, Rui Huang

Clin Mol Hepatol. 2025;31(2):e140-e142. Published online December 3, 2024

DOI: https://doi.org/10.3350/cmh.2024.0960

View: 1030 Download: 30 Web of Science: 1 Crossref: 1

Global inequality in the burden of hepatitis B from 1990 to 2021: Findings from the global burden of disease study 2021: Letter to the editor on “Comprehensive approach to controlling chronic hepatitis B in China”

Chunlong Liu, Jiangtao Yu

Clin Mol Hepatol. 2025;31(2):e134-e136. Published online December 17, 2024

DOI: https://doi.org/10.3350/cmh.2024.1085

View: 1388 Download: 85 Web of Science: 1 Crossref: 1

Letter to the editor on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”

Hai Xu, Yong Zhou, Huikun Wu

Clin Mol Hepatol. 2025;31(2):e125-e127. Published online December 17, 2024

DOI: https://doi.org/10.3350/cmh.2024.1087

View: 1132 Download: 35 Crossref: 1

MAFLD or MASLD: Which better represents the prognosis of the steatotic liver population: Letter to the editor on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”

Ying Wang, Shengfeng Wang, Xiude Fan, Jiajun Zhao, Yongfeng Song

Clin Mol Hepatol. 2025;31(2):e128-e133. Published online December 26, 2024

DOI: https://doi.org/10.3350/cmh.2024.1008

View: 1572 Download: 79 Web of Science: 2 Crossref: 2

Tacrolimus levels and variability in CKD and ESRD risk post-liver transplant: Letter to the editor on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”

Rui Shi, Minghua Wang

Clin Mol Hepatol. 2025;31(2):e137-e139. Published online January 9, 2025

DOI: https://doi.org/10.3350/cmh.2024.1159

View: 957 Download: 45 Web of Science: 1 Crossref: 1

Letter to the editor on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”

Wei Wang, Yating Xie, Ailei Xu

Clin Mol Hepatol. 2025;31(2):e143-e144. Published online February 18, 2025

DOI: https://doi.org/10.3350/cmh.2025.0140

View: 904 Download: 36

Presence of liver fibrosis in chronic hepatitis B patients with varying serum hepatitis B virus DNA levels: Letter to the editor on “Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B”

Jian Wang, Shaoqiu Zhang, Chuanwu Zhu, Yuanwang Qiu, Chao Wu, Rui Huang

Clin Mol Hepatol. 2025;31(1):e27-e30. Published online August 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0602

View: 1289 Download: 52 Crossref: 1

Letter to the editor on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”

Meng-Che Wu, Hui-Chin Chang, Yi-Sheng Jhang, Shuo-Yan Gau

Clin Mol Hepatol. 2025;31(1):e13-e14. Published online September 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0682

View: 1456 Download: 108 Crossref: 1

Letter to the editor on “Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis”

Xiao-Song Li, Xi-Ping Shen, Hang Li

Clin Mol Hepatol. 2025;31(1):e15-e16. Published online September 12, 2024

DOI: https://doi.org/10.3350/cmh.2024.0784

View: 1151 Download: 44 Web of Science: 1 Crossref: 1

Sex-specific associations of metabolic dysfunction-associated steatotic liver disease with cardiovascular outcomes

Meng-Yuan Miao, Jie-Qiong Lyu, Wei Jiang, Zhong-Yue Liu, Guo-Chong Chen

Clin Mol Hepatol. 2025;31(1):e35-e38. Published online September 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0719

View: 1402 Download: 75 Web of Science: 1 Crossref: 1

Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma

Binghua Li, Jingyuan Wen, Zhu Xu, Peng Yan, Bing Han, Decai Yu

Clin Mol Hepatol. 2025;31(1):e31-e34. Published online September 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0628

View: 1477 Download: 112 Web of Science: 1 Crossref: 2

Accountability in AI medicine: A critical appraisal of ChatGPT in patient self-management and screening

Jiawen Wang, Tian Xia

Clin Mol Hepatol. 2025;31(1):e1-e2. Published online September 26, 2024

DOI: https://doi.org/10.3350/cmh.2024.0769

View: 1184 Download: 50

Comparison of the therapeutic effects of transarterial radioembolization and tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis

Hang Li, Hua Lu, Xi-Ping Shen, Xiao-Song Li

Clin Mol Hepatol. 2025;31(1):e3-e4. Published online October 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0832

View: 1253 Download: 52 Crossref: 1

Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults

Donghee Kim, Won Kim, Aijaz Ahmed

Clin Mol Hepatol. 2025;31(1):e5-e7. Published online October 8, 2024

DOI: https://doi.org/10.3350/cmh.2024.0849

View: 1178 Download: 45 Web of Science: 1 Crossref: 1

Development of risk scores for prognosis prediction among patients with early-stage hepatocellular carcinoma

Xiping Shen, Ji Wu

Clin Mol Hepatol. 2025;31(1):e17-e18. Published online October 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0794

View: 1238 Download: 51 Crossref: 1

Letter regarding “Prevalence of clinically significant liver fibrosis in the general population”

Wei Feng, Qile Wang, Qingwang Ye

Clin Mol Hepatol. 2025;31(1):e21-e22. Published online October 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0887

View: 1259 Download: 30 Web of Science: 1

Chronic hepatitis B, extrahepatic malignancies and the use of antiviral drugs

Meng-Che Wu, Shih-Chi Yang, Shuo-Yan Gau

Clin Mol Hepatol. 2025;31(1):e19-e20. Published online October 17, 2024

DOI: https://doi.org/10.3350/cmh.2024.0906

View: 1041 Download: 35

Urgent need for education on hepatocellular carcinoma surveillance among high-risk population in China

Lei Cai, Chao Li, Li-Yang Sun, Yong-Kang Diao, Ming-Da Wang, Tian Yang

Clin Mol Hepatol. 2025;31(1):e39-e43. Published online October 23, 2024

DOI: https://doi.org/10.3350/cmh.2024.0813

View: 1149 Download: 58 Crossref: 1

Insights on risk score development: Considerations for early-stage hepatocellular carcinoma models

Zhanna Zhang, Gongqiang Wu

Clin Mol Hepatol. 2025;31(1):e8-e9. Published online November 6, 2024

DOI: https://doi.org/10.3350/cmh.2024.0958

View: 1104 Download: 42 Web of Science: 1 Crossref: 1

Grading severity of microvascular invasion in hepatocellular carcinoma: More details, more significance

Xiu-Ping Zhang, Fei-Fan Wu, Tian-Chen Zhang, Zhen-Qi Li, Ming-Gen Hu, Rong Liu

Clin Mol Hepatol. 2025;31(1):e10-e12. Published online November 26, 2024

DOI: https://doi.org/10.3350/cmh.2024.0986

View: 1594 Download: 61

Comment: Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus

Xinpu Miao, Haidong Wu, Jinrong Xu, Wei Cheng

Clin Mol Hepatol. 2025;31(1):e23-e24. Published online November 26, 2024

DOI: https://doi.org/10.3350/cmh.2024.1035

View: 1016 Download: 25

The fibrosis-4 index for advanced liver fibrosis in NAFLD with T2DM: Half a loaf is better than no bread

Zeyu Wang, Dong Wan, Meidong Xu, Yong Jiang

Clin Mol Hepatol. 2025;31(1):e25-e26. Published online December 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0993

View: 1175 Download: 43 Crossref: 1

Leukocyte telomere shortening in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality

Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed

Clin Mol Hepatol. 2024;30(4):982-986. Published online August 27, 2024

DOI: https://doi.org/10.3350/cmh.2024.0691

View: 2025 Download: 67 Web of Science: 1 Crossref: 1

Differences in major adverse cardiovascular events of metabolic dysfunction-associated steatotic liver disease by race and ethnicity: Letter to the editor on “Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study”

Hui-Chin Chang, Wen-Chieh Liao, Yi-Jen Fang, Shiu-Jau Chen, Shuo-Yan Gau

Clin Mol Hepatol. 2024;30(4):978-981. Published online August 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0565

View: 1716 Download: 58 Web of Science: 1 Crossref: 2

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

Viewed By 12590	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7645	Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target
Viewed By 7132	MAFLD: How is it different from NAFLD?
Viewed By 5686	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 5615	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment

Cited By 366	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 354	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 232	MAFLD: How is it different from NAFLD?
Cited By 122	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 116	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis